Abstract

We evaluated the frequency of translocation renal cell carcinoma (RCC) by reverse transcription polymerase chain reaction (RT-PCR) and how well the TFE3 immunoreactivity is concordant with TFE3 gene translocation status proved by fluorescence in situ hybridization (FISH) assay and RT-PCR. TFE3 and Cathepsin K expression was analyzed by immunohistochemistry in 185 RCC cases, and 48 cases either of more than weak expression of TFE3 or of positivity for Cathepsin K were done for FISH analysis and RT-PCR. All the RT-PCR positive cases were confirmed by cloning and sequencing. Of the 14 cases with strong nuclear TFE3 expression, 12 showed a break-apart signal by FISH. ASPL- and PRCC-TFE3 translocations were detected in 13 and one case, respectively, by RT-PCR. Of 21 cases with weak TFE3 expression, five were translocation-positive by FISH. ASPL-, PRCC-, and PSF-TFE3 translocations were detected by RT-PCR (n=3, 3, and 1, respectively). All 13 TFE3-negative/cathepsin K-positive cases were negative by FISH and two each harbored ASPL- and PRCC-TFE3 translocations that were detected by RT-PCR. A high rate of TFE3 immunoreactivity (8.6%) was confirmed by RT-PCR (13.5%) and FISH (9.7%). Higher translocation rate of RT-PCR means RT-PCR detected translocation in TFE3 weak expression group and only cathepsin K positive group more specifically than FISH. Thus, RT-PCR would complement FISH analysis for detecting translocation RCC with fusion partners.

Highlights

  • Xp11 translocation renal cell carcinoma (RCC) is characterized by chromosome translocations involving the TFE3 gene at the Xp11 breakpoint [1, 2]

  • To compare three methods for diagnosing Xp11 translocation RCC, the present study examined the results of TFE3 immunohistochemistry, fluorescence in situ hybridization (FISH), and reverse transcription polymerase chain reaction (RT-PCR) using formalin fixed paraffin embedded (FFPE) tissue

  • An initial diagnosis is usually made based on immunohistochemical detection of TFE3 or TFEB overexpression in the nucleus [13, 20]

Read more

Summary

Introduction

Xp11 translocation renal cell carcinoma (RCC) is characterized by chromosome translocations involving the TFE3 gene at the Xp11 breakpoint [1, 2]. Fusion partners of TFE3 include PRCC, PSF (SFPQ1), NonO, ASPL (ASPSCR1), CLTC and DVL2 [4, 5] and some studies have indicated that translocation RCCs with different translocations show different morphologic features [6, 7]. Therapies targeting vascular endothelial growth factor receptor and mammalian target of rapamycin may benefit patients with Xp11 translocation RCC [8, 9]; the MET signaling pathway is another possible target, since it is activated by ASPL-TFE3 fusion [10]. Differentiating Xp11 translocation RCC from other subtypes is of clinical importance and more than of academic interest

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.